Colorectal Cancer

Austin, TX

111 Colorectal Cancer Trials near Austin, TX

Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

ATX-559 for Cancer

San Antonio, Texas
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

100 Participants Needed

LY4066434 for Solid Tumors

San Antonio, Texas
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

750 Participants Needed

RMC-9805 for Solid Cancers

San Antonio, Texas
This trial is testing a new oral drug, RMC-9805, in adults with a specific type of cancer mutation (KRAS G12D). The drug aims to block a faulty gene to potentially stop cancer growth.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

604 Participants Needed

This trial tests a new drug called ABBV-400 for adults with advanced cancers. The study aims to find the best dose and see how well it works, both alone and with other treatments. Patients will receive the drug through an IV and be closely monitored for effects and side effects.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

520 Participants Needed

MRTX1133 for Solid Cancers

San Antonio, Texas
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

386 Participants Needed

This trial tests a new drug, BDC-1001, alone and with another drug, in patients with advanced HER2-positive cancers. BDC-1001 aims to attack cancer cells directly, and the other drug boosts the immune system to fight the cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

175 Participants Needed

MGC028 for Solid Tumors

San Antonio, Texas
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

124 Participants Needed

This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

494 Participants Needed

TST003 for Cancer

San Antonio, Texas
This trial tests TST003, a new drug for treating advanced cancers. It focuses on patients with advanced or metastatic solid tumors and later specifically on colorectal cancer. The drug is given through a vein, and doctors will monitor its safety, side effects, and effectiveness.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

111 Participants Needed

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

97 Participants Needed

BMS-986523 for Solid Tumors

San Antonio, Texas
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

252 Participants Needed

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

180 Participants Needed

LY3537982 for Cancer

San Antonio, Texas
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

540 Participants Needed

ALTA3263 for Cancer

San Antonio, Texas
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

130 Participants Needed

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

392 Participants Needed

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

630 Participants Needed

BMF-219 for Lung Cancer

San Antonio, Texas
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
No Placebo Group

Trial Details

Trial Status:Recruiting

90 Participants Needed

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

17 Participants Needed

WEF-001 for Cancer

San Antonio, Texas
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

110 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

115 Participants Needed

FOG-001 for Cancer

San Antonio, Texas
This trial is testing FOG-001, a new medicine, to see if it is safe and effective for patients with advanced or spreading solid tumors. FOG-001 works by blocking certain proteins to stop cancer cells from growing.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

575 Participants Needed

XMT-2056 for Breast Cancer

San Antonio, Texas
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

162 Participants Needed

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
No Placebo Group

Trial Details

Trial Status:Recruiting

80 Participants Needed

ADC for Cancer

San Antonio, Texas
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

150 Participants Needed

COM902 for Cancer

San Antonio, Texas
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

110 Participants Needed

FMC-376 for Solid Tumors

San Antonio, Texas
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

403 Participants Needed

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

287 Participants Needed

This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

216 Participants Needed

This trial tests a new therapy using modified immune cells in adults with advanced cancers. The treatment aims to target and destroy cancer cells with a specific marker found in various cancers, including breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

180 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Colorectal Cancer clinical trials in Austin, TX pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Colorectal Cancer clinical trials in Austin, TX work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in Austin, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Austin, TX for Colorectal Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Austin, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Colorectal Cancer medical study in Austin, TX?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Colorectal Cancer clinical trials in Austin, TX?

Most recently, we added Pumitamig + Chemotherapy for Colorectal Cancer, BMS-986523 for Solid Tumors and STRO-004 + Pembrolizumab for Metastatic Cancer to the Power online platform.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security